Citius Pharmaceuticals Secures $6 Million with Successful Direct Offering for LYMPHIR™ Launch

Citius Pharmaceuticals Fuels Growth with Successful Direct Offering

Citius Pharmaceuticals Inc. announces a significant financial development with the successful closing of a registered direct offering on October 21, 2025. The biopharmaceutical company, which focuses on innovative critical care products, sells 3,973,510 shares of common stock at a price of $1.51 per share. This transaction, facilitated by H.C. Wainwright & Co. as the exclusive placement agent, generates approximately $6 million in gross proceeds before fees and expenses. This capital influx is pivotal for Citius as it prepares for the commercial launch of its FDA-approved product, LYMPHIR™, aimed at targeted immunotherapy applications.

The successful offering underlines Citius Pharmaceuticals' strategic approach to funding its operational needs and development initiatives. The net proceeds from this transaction are earmarked for several critical areas: primarily, they will support the market introduction of LYMPHIR™, which received FDA approval in August 2024 for treating specific conditions. The funds will also facilitate ongoing development for other product candidates, reinforcing the company's commitment to advancing innovative treatments in the critical care sector. This strategic financial maneuver not only enhances Citius's market presence but also solidifies its position within the biopharmaceutical landscape.

Moreover, the direct offering is conducted under a "shelf" registration statement filed with the SEC, allowing Citius to streamline future capital-raising efforts. This flexibility is crucial as the biopharmaceutical industry often requires substantial funding for continued research and development. By leveraging this regulatory framework, Citius demonstrates an agile business strategy aimed at maximizing opportunities for growth and innovation. The details of the offering and additional information are accessible via the SEC's website, reflecting the company's transparency and commitment to investor communication.

In addition to its financial achievements, Citius Pharmaceuticals emphasizes the potential impact of LYMPHIR™ on patient care. The approval of this innovative therapy marks a significant advancement in immunotherapy, showcasing the company's dedication to addressing unmet medical needs in critical care. Citius aims to leverage this momentum to not only enhance patient outcomes but also to establish itself as a leader in the biopharmaceutical industry.

As Citius Pharmaceuticals continues to navigate the complexities of the biopharmaceutical landscape, the successful closing of this direct offering represents a crucial step in its growth trajectory. The company's focus on developing first-in-class critical care products positions it well for future advancements and contributions to patient care.